In addition to GLP-1R agonists, orally administrated DPP4-inhibitors, e.g., sitagliptin and saxagliptin , which are known to potentiate the effect of endogenous GLP-1 by inhibiting its degradation, have also been clinically studied as protective agents against retinopathy (Svenningsson et al., 2016) in T2D patients, although DPP4-inhibitors cannot cross the blood-brain barrier (Mousa and Ayoub, 2019)
Both have the same active ingredient, tirzepatide, but are FDA-approved for different indications, including: Mounjaro for blood sugar control in patients with type 2 diabetes
Applies to the following strengths: 200 mg/mL
LegoChem partners Samsung Biologics for ADC programSanofis spinoff EUROAPI marked 2024 as a transition year, setting in motion its Focus-27 plan for profitable growth in the future
She took the time to really understand my skin, customize a treatment plan, and guide me through every step with so much care and knowledge